Randomized Trials
RCT: Safety and efficacy of Eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures.
20 Jun, 2022 | 01:01h | UTCSafety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial – The Lancet Neurology (link to abstract – $ for full-text)
#CCR22 – RCT: Intravenous Vitamin C increases the risk of death or persistent organ dysfunction in adults with sepsis in the intensive care unit.
16 Jun, 2022 | 11:13h | UTCRelated:
Commentary on Twitter
https://twitter.com/NEJM/status/1536991910006468608
RCT: Discontinuation of Infliximab therapy in patients with Crohn’s disease.
15 Jun, 2022 | 10:54h | UTCDiscontinuation of Infliximab Therapy in Patients with Crohn’s Disease – NEJM Evidence
RCT: Marine Omega-3 Fatty acid supplementation does not reduce the incidence of dry eye disease in healthy adults.
10 Jun, 2022 | 12:25h | UTCEfficacy of Marine ω-3 Fatty Acid Supplementation vs Placebo in Reducing Incidence of Dry Eye Disease in Healthy US Adults: A Randomized Clinical Trial – JAMA Ophthalmology (free for a limited period)
Invited Commentary: Another Disappointment for ω-3 Fatty Acid and Dry Eye Disease – JAMA Ophthalmology (free for a limited period)
Commentary on Twitter
In this randomized clinical trial, daily supplementation with marine omega-3 fatty acids (1 gram) for a median of 5.3 years had no significant effect on the incidence of diagnosed #dryeyedisease (DED) or reported DED symptoms. https://t.co/iTBONh6CZK
— JAMA Ophthalmology (@JAMAOphth) June 9, 2022
Neck circumference measurement for surveillance and early detection of hemorrhage after thyroidectomy: a diagnostic accuracy study.
10 Jun, 2022 | 11:39h | UTCNeck Circumference Measurement for Surveillance and Early Detection of Hemorrhage After Thyroidectomy: A Diagnostic Accuracy Study – JAMA Otolaryngology-Head & Neck Surgery (free for a limited period)
Commentary on Twitter
Study evaluated neck circumference measurements as a diagnostic tool to improve patient’s safety in thyroid surgery. An increase of 7% or more seemed to be specific for post-thyroidectomy hemorrhage along with other clinical signs. https://t.co/HQqjv3svRx #thyroidectomy
— JAMA Otolaryngology – Head & Neck Surgery (@JAMAOto) June 9, 2022
RCT: Effect of electronic symptom monitoring on patient-reported outcomes among patients with metastatic cancer.
8 Jun, 2022 | 11:14h | UTCEffect of Electronic Symptom Monitoring on Patient-Reported Outcomes Among Patients With Metastatic Cancer: A Randomized Clinical Trial – JAMA (free for a limited period)
Related:
Digital remote monitoring plus usual care versus usual care in patients treated with oral anticancer agents: the randomized phase 3 CAPRI trial – Nature Medicine (if the link is paywalled, try this one)
Key components of successful digital remote monitoring in oncology – Nature Medicine
Do we need to reconsider how we design and conduct randomized controlled trials?
8 Jun, 2022 | 10:56h | UTC
RCT: Effect of intraoperative handovers of anesthesia care on mortality, readmission, or postoperative complications among adults.
6 Jun, 2022 | 11:04h | UTCEffect of Intraoperative Handovers of Anesthesia Care on Mortality, Readmission, or Postoperative Complications Among Adults: The HandiCAP Randomized Clinical Trial – JAMA (free for a limited period)
Related Study: Association Between Handover of Anesthesia Care and Adverse Postoperative Outcomes Among Patients Undergoing Major Surgery – JAMA
Commentary on Twitter
In this RCT, among adults undergoing extended surgical procedures, there was no difference bw handover of anesthesia care compared w no handover of care in the primary outcome of mortality, readmission, & serious postoperative complications within 30 days.https://t.co/FpGFZk47x7
— JAMA (@JAMA_current) June 4, 2022
RCTs: Efficacy, safety, and tolerability of Centanafadine sustained-release tablets in adults with attention-deficit/hyperactivity disorder.
3 Jun, 2022 | 11:21h | UTC
RCT: Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer.
2 Jun, 2022 | 10:49h | UTCDurvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer – NEJM Evidence
Commentary on Twitter
Durvalumab, with gemcitabine plus cisplatin, increased median overall survival, 12.8 months versus 11.5 months, in patients with previously untreated unresectable, recurrent or metastatic biliary tract cancer. https://t.co/SaeUxfGfWd#OncTwitter #MedTwitter #Cholangiocarcinoma pic.twitter.com/NZeVljWnyu
— NEJM Evidence (@NEJMEvidence) June 1, 2022
RCT: Effect of reflectance confocal microscopy for suspect lesions on diagnostic accuracy in melanoma.
2 Jun, 2022 | 10:41h | UTC
Commentary on Twitter
In this RCT, adjunctive use of reflectance confocal microscopy for suspicious lesions is proven to reduce unnecessary excisions and removes all aggressive melanomas at baseline in a real-life, prospective clinical decision making setting. https://t.co/cWJu9TlaEH
— JAMA Dermatology (@JAMADerm) June 1, 2022
Randomized Crossover Trial: Effect of a ketogenic diet vs. Mediterranean diet on HbA1c in individuals with prediabetes and type 2 diabetes mellitus.
2 Jun, 2022 | 10:37h | UTC
Commentary from one of the authors on Twitter (thread – click for more)
The results of the #KetoMedStudy are finally out! How low-carb do you need to go for glucose control? Is keto better than a low-carb Mediterranean diet with no refined grains (Med-Plus)? 👉 https://t.co/XHUqahXL2m#keto #ketodiet #MediterraneanDiet #ketomedstudy #luciaaronica
— Dr Aronica (@LuciaAronica) June 1, 2022
RCTs: Favipiravir treatment of uncomplicated influenza in adults.
1 Jun, 2022 | 11:27h | UTCCommentary: Mixed Bag for Antiviral Favipiravir in Flu — Two phase III trials show conflicting results on clinical improvement – MedPage Today (free registration required)
RCT: Risankizumab as maintenance therapy for moderately to severely active Crohn’s disease.
30 May, 2022 | 11:14h | UTCRisankizumab as maintenance therapy for moderately to severely active Crohn’s disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial – The Lancet (link to abstract – $ for full-text)
RCTs: Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis.
30 May, 2022 | 11:12h | UTCUpadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials – The Lancet (link to abstract – $ for full-text)
Randomized crossover trial: Thrice daily consumption of a premeal shot containing a low dose of whey protein increases time in euglycemia during 7 days of free-living in individuals with type 2 diabetes.
30 May, 2022 | 10:57h | UTCNews Release: Protein supplement helps control Type 2 diabetes – Newcastle University
RCT: Efficacy and safety of TRC105 plus pazopanib vs. pazopanib alone for treatment of patients with advanced angiosarcoma.
27 May, 2022 | 11:15h | UTCCommentaries:
Addition of Carotuximab to Pazopanib in Advanced Angiosarcoma – The ASCO Post
Commentaries on Twitter
A phase III trial in 123 patients with advanced-stage angiosarcoma reveals no significant difference in mPFS with pazopanib plus the anti-endoglin (CD105) mAb carotuximab vs pazopanib alone: https://t.co/TPPFRNCOoC #scmsm #caxtx
— NatureRevClinOncol (@NatRevClinOncol) April 5, 2022
First randomized trial in angiosarcoma demonstrates no signif difference in progression-free survival for combo of novel angiogenesis inhibitor carotuximab + pazopanib vs. pazopanib alone in advanced angiosarcoma. https://t.co/f1Z5EjOdK2 pic.twitter.com/qf3Tez9VU2
— JAMA Oncology (@JAMAOnc) March 31, 2022
RCT: The addition of Metformin to standard therapy did not improve outcomes in patients with breast cancer.
25 May, 2022 | 11:49h | UTCEffect of Metformin vs Placebo on Invasive Disease–Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical Trial – JAMA (free for a limited period)
Editorial: Who Will Benefit From Metformin? – JAMA Oncology
RCT: Tenecteplase vs. alteplase for the management of acute ischemic stroke.
20 May, 2022 | 10:43h | UTCTenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial – The Lancet Neurology (link to abstract – $ for full-text)
Perspective: The need for increased pragmatism in cardiovascular clinical trials.
19 May, 2022 | 10:48h | UTCThe need for increased pragmatism in cardiovascular clinical trials – Nature Reviews Cardiology (if the link is paywalled, try this one)
Related: A roadmap of strategies to support cardiovascular researchers: from policy to practice – Nature Reviews Cardiology (if the link is paywalled, try this one)
Commentary on Twitter
In our latest Review, @ShahzebKhanMD and colleagues discuss the need for increased pragmatism in #cardiovascular clinical trials: https://t.co/LUlrPKusAk pic.twitter.com/cxAYmD2nyS
— Nature Reviews Cardiology (@NatRevCardiol) May 17, 2022
Study designs for clinical trials applied to personalized medicine: a scoping review.
19 May, 2022 | 10:36h | UTCStudy designs for clinical trials applied to personalised medicine: a scoping review – BMJ Open
Visualizing harms in publications of randomized controlled trials: consensus and recommendations.
17 May, 2022 | 10:47h | UTCCommentary: Visualising harms: barely scratching the surface – The BMJ
RCT: Efficacy and safety of fenfluramine for the treatment of seizures associated With Lennox-Gastaut Syndrome.
16 May, 2022 | 01:29h | UTCCommentaries:
Fenfluramine Found Effective for Treatment of Lennox-Gastaut Syndrome Seizures – NeurologyToday
Fenfluramine Seems Effective for Lennox-Gastaut Syndrome – HealthDay
Commentary on Twitter
In this randomized clinical trial, fenfluramine was a safe and effective treatment option for patients with Lennox-Gastaut syndrome. https://t.co/Ukopx9cV9r @Zogenix pic.twitter.com/dRetoOZSiB
— JAMA Neurology (@JAMANeuro) May 2, 2022
Endometrial scratch to increase live birth rates in women undergoing first-time in vitro fertilization: RCT and systematic review.
12 May, 2022 | 07:53h | UTCRelated:
Phase 2 RCT: Anti-tumor necrosis factor therapy for early-stage Dupuytren’s disease.
9 May, 2022 | 01:38h | UTCNews Release: Breakthrough in treatment for Dupuytren’s disease – University of Oxford
Commentary: Treatment for finger-bending disease may be ‘gamechanger’ – The Guardian
Commentary on Twitter
NEW RESEARCH—Intranodular injections of anti-tumour necrosis factor therapy (adalimumab) for early-stage Dupuytren's disease: a phase 2b, randomised, double-blind, placebo-controlled trial https://t.co/Jz9QUJEzS8 #LancetRheumatology #OpenAccess pic.twitter.com/mcZj9GK4l4
— The Lancet Rheumatology (@TheLancetRheum) May 4, 2022